美股期权个股详情
BMEA240920C10000
- 0.20
- -0.15-42.86%
延时15分钟行情收盘价 08/30 16:00 (美东)
0.20最高价0.18最低价
0.18今开0.35昨收3张成交量1063张未平仓合约数10.00行权价56.00成交额130.03%隐含波动率39.15%溢价2024/09/20到期日0.00内在价值100合约乘数19天距到期日0.20时间价值100合约规模美式期权类型0.1895Delta0.1236Gamma36.65杠杆倍数-0.0155Theta0.0006Rho6.94有效杠杆0.0046Vega
Biomea Fusion股票讨论
The pause on clinical trials seems to be a result of the explosion of industry regulations in recent years. From 2022 through 2024, the FDA has implemented "additional steps" to clinical trials, including bringing in outside agencies to help with oversight.
Red tape and bureaucracy, not BEMA, caused this pause. All the research I've done shows the pause was premature and overly cautious.
暂无评论